MIRMirion Technologies, Inc.
Price
-32%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality strong, nothing alarming, price roughly fair, growing in the filings, the market undecided.
At Mirion, we deliver vital protection that unlocks the transformative potential of radiation to move science, industry and medicine forward. For more than 60 years Mirion and our predecessor companies have provided products, services, and software that allow customers to safely leverage the power of ionizing radiation for applications that benefit the health, safety, vitality, and technological progress of the human experience.
In the company’s own words · 10-K filed Feb 19, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Mirion Technologies, Inc. (MIR) reported revenue of $267M in Q2 2026 (quarter ended Jun 30, 2026), up 20% from the same quarter a year earlier. That came with a gross margin of 50% and net income of $7.7M (2.9% of revenue). For the full year FY2025, revenue was $925M (+7.5% year on year) and net income $29M. Its largest product in Q2 2026 was Nuclear Power at $118M, 44% of the disclosed total, well ahead of Cancer Care at 24%. The next results filing is expected around Oct 27, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 31, 2026On August 31, 2026, the Board of Directors (the "Board") of Mirion Technologies, Inc. (the "Company") approved a new share repurchase program (the "2026 Repurchase Program") authorizing the repurchase of up to $250 million of the Company's outstanding Class A common stock.Other event · Form 8-K
- Jul 28, 2026Mirion Announces Second Quarter 2026 Financial Results.Earnings release · press release
- Jul 2, 2026On July 2, 2026, Mirion Technologies, Inc. (the " Company ") entered into a letter agreement and a secondment addendum with Mr. Loïc Eloy, the Company's President, Nuclear & Safety Group and named executive officer, in connection with his expatriation assignment and secondment from France to the United States.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $266.8MThe company’s own SEC segment disclosure.
- Nuclear Power$118.1M44%
- Cancer Care$62.8M24%
- Other Research$39.0M15%
- Labs And Research$29.1M11%
- Other Care$17.8M7%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Specialty Industrial Machinery
Ranks #29 of 33 by RyuScore